HB 192 -- Health Insurance

Sponsor: Luetkemeyer

Current law requires insurers to provide coverage to cancer patients for drugs and devices used in clinical trails, even if those drugs and devices have not been approved by the U. S. Food and Drug Administration (FDA) for use in treating the patient's particular condition. This bill limits the mandated coverage to drugs and devices that the FDA has approved for the patient's particular condition.